Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Reply: Accelerometers: A Useful Technology in HF Research?

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Hemodynamic Determinants of Activity Measured by Accelerometer in Patients With Stable Heart Failure

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Prognostic Value of Peak Oxygen Uptake in Patients Supported With Left Ventricular Assist Devices (PRO-VAD)

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Mineralocorticoid receptor antagonist improves cardiac structure in Type 2 Diabetes: Data from the MIRAD Trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists: An Analysis of DAPA-HF

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. The importance of addressing multiple risk markers in type 2 diabetes: Results from the LEADER and SUSTAIN 6 trials

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Copeptin and renal function decline, cardiovascular events and mortality in type 1 diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  • John J V McMurray
  • David C Wheeler
  • Bergur V Stefánsson
  • Niels Jongs
  • Douwe Postmus
  • Ricardo Correa-Rotter
  • Glenn M Chertow
  • Fan Fan Hou
  • Peter Rossing
  • C David Sjöström
  • Scott D Solomon
  • Robert D Toto
  • Anna Maria Langkilde
  • Hiddo J L Heerspink
  • DAPA-CKD Trial Committees and Investigators
View graph of relations

OBJECTIVES: The purpose of this paper was to investigate the effects of dapagliflozin in chronic kidney disease (CKD) patients, with and without heart failure (HF).

BACKGROUND: Patients with CKD, with and without type 2 diabetes, were enrolled in the DAPA-CKD (Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease) trial. Some patients had HF at baseline.

METHODS: A total of 4,304 participants were randomized to dapagliflozin 10 mg daily or placebo. The primary composite endpoint was ≥50% decline in estimated glomerular filtration rate, end-stage kidney disease, or kidney/cardiovascular death. Secondary endpoints were a kidney composite (primary endpoint minus cardiovascular death), the composite of cardiovascular death/HF hospitalization, and all-cause death. Analysis of outcomes according to HF history was prespecified.

RESULTS: HF patients (n = 468; 11%) were older and had more coronary disease, atrial fibrillation, and type 2 diabetes. Mean estimated glomerular filtration rate was similar in patients with and without HF. Rates of HF hospitalization/cardiovascular death and death from any cause were higher in HF patients, but the secondary kidney failure outcome occurred at the same rate in people with and without HF. Dapagliflozin reduced the risk of the primary outcome equally in patients with HF (HR: 0.58 [95% CI: 0.37-0.91]) and without HF (HR: 0.62 [95% CI: 0.51-0.75]) (P interaction = 0.59). The proportional risk-reductions were similar in patients with and without HF for the cardiovascular death/HF hospitalization composite (HR: 0.68 [95% CI: 0.44-1.05] vs HR: 0.70 [95% CI: 0.51-0.97], respectively; P interaction = 0.90), and all-cause death (HR: 0.56 [95% CI: 0.34-0.93] vs HR: 0.73 [95% CI: 0.54-0.97], respectively; P interaction = 0.39), although absolute risk reductions were larger in HF patients. Adverse event rates were low and did not differ among patients with or without HF.

CONCLUSIONS: Dapagliflozin reduced the risk of kidney failure and cardiovascular death/HF hospitalization and prolonged survival in CKD patients with or without type 2 diabetes, independently of history of HF. (A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease [DAPA-CKD]; NCT03036150).

Original languageEnglish
JournalJACC. Heart failure
Volume9
Issue number11
Pages (from-to)807-820
Number of pages14
ISSN2213-1779
DOIs
Publication statusPublished - Nov 2021

Bibliographical note

Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

    Research areas

  • cardiovascular disease, chronic kidney disease, dapagliflozin, heart failure, SGLT2 inhibitor

ID: 67682742